1 JANUARY – 31 DECEMBER 2022
Increased organic growth
NET SALES
EBITA
EARNINGS GROWTH
EBITA R12 MONTHS
P/WC
Increased organic growth in both business areas
AddLife's sales in the fourth quarter increased by 9 percent year-on-year. As expected, COVID-19 related sales continued to decline compared with both the fourth quarter of 2021 and the third quarter of 2022. In Labtech, the organic growth rate excluding COVID-19 was 6 percent and in Medtech 5 percent. Organic growth excluding COVID-19 for the Group was 6 percent, a clear improvement compared with the previous quarter.
A leading player in Life Science
AddLife is a listed Swedish Medtech company active on the European market. AddLife owns and acquires companies in niche segments with offerings aimed primarily at the healthcare sector, from research to medical care. The subsidiaries are divided into two business areas. Labtech offers products, solutions and a wide range of diagnostic services, biomedical research and laboratory analysis. Medtech offers products, solutions and services in medical technology and home care.
Acquisitions during the financial year
During the financial year, five acquisitions were completed. These acquisitions are estimated to contribute with annual net sales of approximately SEK 850m and approximately 350 employees.
